用铜离子加载的半孔生物活性眼镜增强了冷凝的静血效果,用于急性和持续性出血
Qixiu Hou1,2,3, Xu He4, Mengting Guo1,2,3
1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215500, China.
Journal of nanobiotechnology
|February 12, 2025
概括
一种新的冷凝敷料,GP@MBG-Cu-TA,有效地阻止了急性和持续性出血,并对抗细菌感染. 这种以天然成分为基础的材料在治疗受伤和手术并发症方面表现有前途.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 血液静止和血栓形成
背景情况:
- 失控的出血和感染在治疗受伤,复杂的手术或骨髓衰竭的患者中构成重大挑战,导致高死亡率.
- 现有的治疗方法往往难以同时治疗出血和感染,特别是在凝血功能受损的患者中.
研究的目的:
- 开发一种具有双重血静和抗菌能力的新型冷凝敷料.
- 创造一种能够减少持续出血和增强抗菌活性的天然成分的外部形式.
主要方法:
- 开发一种含有化甲基化凝 (GelMA) 的冷凝 (GP) 装载着含有酸 (TA) 混合铜离子 (Cu2+) 的半孔生物活性玻璃 (MBG).
- GP@MBG-Cu-TA冷凝的结构特征,通过联结证明了粘附性.
- 在体外评估生物相容性,静血和抗菌性质.
- 在大鼠肝损伤和小鼠尾巴截肢模型 (无塑性贫血和血友病A) 中静血疗效的体内评估.
- 在受感染的小鼠皮肤伤口中评估伤口愈合的加速.
主要成果:
- 在实验室中,GP@MBG-Cu-TA冷凝表现出良好的生物相容性,静血性和抗菌能力.
- 在体内研究表明,在急性肝损伤和持续出血模型中增强了静血效应.
- 低温凝显著加快了细菌污染的小鼠的皮肤伤口修复.
- 该物质有效控制了正常和异常凝血功能的人的出血.
结论:
- GP@MBG-Cu-TA冷凝具有双重的静血和抗菌功能.
- 这种新型的冷凝敷料在治疗急性和持续性出血方面是有效的,不管患者的凝血状况如何.
- GP@MBG-Cu-TA冷凝为治疗出血和细菌并发症提供了一个有前途的临床应用候选者.
相关概念视频
01:05Introduction to Hemostasis
5.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
5.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
4.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.9K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
01:22Formation of the Platelet Plug
3.9K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.9K
01:09Coagulation
4.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.3K
01:16Clot Retraction and Fibrinolysis
3.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.5K